Aflibercept

阿柏西普

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAflibercept
Drug Alias NameEyliaVEGF Trap (R1R2)VEGF Trap-eyeAfliberceptumEylea +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaPolypoidal choroidal vasculopathyDrug-Related Side Effects and Adverse Reactions +[33] 
Global Approved IndicationsWet age-related macular degenerationMacular EdemaMacular Degeneration
Approved Indications in ChinaMacular EdemaMacular Degeneration
Original Approved Country/TerritoryUnited States
Original Approved Date2011/11/18
Country/TerritoryCzechiaBelgiumBulgaria +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRegeneron Pharmaceuticals IncBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesYeungnam UniversityJaeb Center For Health Research IncMylan Pharmaceuticals Inc +[11] 
Inactive CompaniesValley Retina InstituteExegenesis Bio CoSoutheast Retina Center Pc +[18] 
Active IndicationsDiabetic macular oedemaPolypoidal choroidal vasculopathyDiabetes Complications +[14] 
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsCentral Serous ChorioretinopathyRetinal Diseases +[19] 

Other Information

ATC CodeL01XX44S01LA05
Related LinksWikipediaDrugBankKEGG